MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of marketable
securities
$292,211K
Proceeds from sales of
property and equipment
$252K
Net cash provided by
(used in) investing...
$10,117K
Effect of exchange rate
changes on cash, cash...
$109K
Canceled cashflow
$282,345K
Net decrease in
cash, cash...
-$7,892K
Canceled cashflow
$10,226K
Proceeds from line of
credit
$5,582K
Proceeds from employee
stock purchase plan
$1,149K
Proceeds from issuance of
common stock under...
$325K
Deferred income taxes
$33,557K
Stock-based compensation
$24,585K
Depreciation and
amortization
$7,579K
Amortization of operating
lease-right-of use assets
$4,396K
Accrued expenses and
other liabilities
$3,970K
Deferred revenue
$3,601K
Provision for excess and
obsolete inventory
$1,703K
Trade accounts
payable
$448K
Loss on disposal of
property and equipment
-$415K
Provision for (benefit
from) credit losses
$413K
Trade accounts
receivable
-$368K
Purchases of marketable
securities
-$278,155K
Purchase of property and
equipment
$4,084K
Purchase of intangible
assets (patents)
$106K
Net cash used in
financing activities
-$13,432K
Canceled cashflow
$7,056K
Net cash provided by
(used in) operating...
-$4,686K
Canceled cashflow
$81,035K
Payment for repurchase
of shares
$15,074K
Repayment of loan
$4,745K
Payments for taxes
related to net share...
$670K
Net loss
-$66,539K
Gain on investments,
accretion, and...
-$5,673K
Inventories
$5,244K
Lease liabilities
$4,146K
Prepaid expenses and
other assets
$2,658K
Legal settlement
liabilities
-$1,133K
Interest expenses for
accretion of the legal...
-$328K
Back
Back
Cash Flow
source: myfinsight.com
Cytek Biosciences, Inc. (CTKB)
Cytek Biosciences, Inc. (CTKB)